Moshi Song1, Yun Chen1, Guohua Gong1, Elizabeth Murphy1, Peter S Rabinovitch1, Gerald W Dorn2. 1. From the Department of Internal Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, MO (M.S., G.G., G.W.D.); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (E.M.); and Department of Pathology, University of Washington, Seattle (P.S.R.). 2. From the Department of Internal Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St. Louis, MO (M.S., G.G., G.W.D.); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (E.M.); and Department of Pathology, University of Washington, Seattle (P.S.R.). gdorn@dom.wustl.edu.
Abstract
RATIONALE: Mitochondrial reactive oxygen species (ROS) are implicated in aging, chronic degenerative neurological syndromes, and myopathies. On the basis of free radical hypothesis, dietary, pharmacological, and genetic ROS suppression has been tested to minimize tissue damage, with remarkable therapeutic efficacy. The effects of mitochondrial-specific ROS suppression in primary mitophagic dysfunction are unknown. OBJECTIVE: An in vivo dose-ranging analysis of ROS suppression in an experimental cardiomyopathy provoked by defective mitochondrial clearance. METHODS AND RESULTS: Mice lacking mitofusin 2 (Mfn2) in hearts have impaired parkin-mediated mitophagy leading to accumulation of damaged ROS-producing organelles and progressive heart failure. As expected, cardiomyocyte-directed expression of mitochondrial-targeted catalase at modest levels normalized mitochondrial ROS production and prevented mitochondrial depolarization, respiratory impairment, and structural degeneration in Mfn2 null hearts. In contrast, catalase expression at higher levels that supersuppressed mitochondrial ROS failed to improve either mitochondrial fitness or cardiomyopathy, revealing that ROS toxicity is not the primary mechanism for cardiac degeneration. Lack of benefit from supersuppressing ROS was associated with failure to invoke secondary autophagic pathways of mitochondrial quality control, revealing a role for ROS signaling in mitochondrial clearance. Mitochondrial permeability transition pore function was normal, and genetic inhibition of mitochondrial permeability transition pore function did not alter mitochondrial or cardiac degeneration, in Mfn2 null hearts. CONCLUSIONS: Local mitochondrial ROS (1) contribute to mitochondrial degeneration and (2) activate mitochondrial quality control mechanisms. A therapeutic window for mitochondrial ROS suppression should minimize the former while retaining the latter, which we achieved by expressing lower levels of catalase.
RATIONALE: Mitochondrial reactive oxygen species (ROS) are implicated in aging, chronic degenerative neurological syndromes, and myopathies. On the basis of free radical hypothesis, dietary, pharmacological, and genetic ROS suppression has been tested to minimize tissue damage, with remarkable therapeutic efficacy. The effects of mitochondrial-specific ROS suppression in primary mitophagic dysfunction are unknown. OBJECTIVE: An in vivo dose-ranging analysis of ROS suppression in an experimental cardiomyopathy provoked by defective mitochondrial clearance. METHODS AND RESULTS:Mice lacking mitofusin 2 (Mfn2) in hearts have impaired parkin-mediated mitophagy leading to accumulation of damaged ROS-producing organelles and progressive heart failure. As expected, cardiomyocyte-directed expression of mitochondrial-targeted catalase at modest levels normalized mitochondrial ROS production and prevented mitochondrial depolarization, respiratory impairment, and structural degeneration in Mfn2 null hearts. In contrast, catalase expression at higher levels that supersuppressed mitochondrial ROS failed to improve either mitochondrial fitness or cardiomyopathy, revealing that ROStoxicity is not the primary mechanism for cardiac degeneration. Lack of benefit from supersuppressing ROS was associated with failure to invoke secondary autophagic pathways of mitochondrial quality control, revealing a role for ROS signaling in mitochondrial clearance. Mitochondrial permeability transition pore function was normal, and genetic inhibition of mitochondrial permeability transition pore function did not alter mitochondrial or cardiac degeneration, in Mfn2 null hearts. CONCLUSIONS: Local mitochondrial ROS (1) contribute to mitochondrial degeneration and (2) activate mitochondrial quality control mechanisms. A therapeutic window for mitochondrial ROS suppression should minimize the former while retaining the latter, which we achieved by expressing lower levels of catalase.
Authors: Dao-Fu Dai; Simon C Johnson; Jason J Villarin; Michael T Chin; Madeline Nieves-Cintrón; Tony Chen; David J Marcinek; Gerald W Dorn; Y James Kang; Tomas A Prolla; Luis F Santana; Peter S Rabinovitch Journal: Circ Res Date: 2011-02-10 Impact factor: 17.367
Authors: Kyriakos N Papanicolaou; Ramzi J Khairallah; Gladys A Ngoh; Aristide Chikando; Ivan Luptak; Karen M O'Shea; Dushon D Riley; Jesse J Lugus; Wilson S Colucci; W Jonathan Lederer; William C Stanley; Kenneth Walsh Journal: Mol Cell Biol Date: 2011-01-18 Impact factor: 4.272
Authors: Claudia J Lagranha; Anne Deschamps; Angel Aponte; Charles Steenbergen; Elizabeth Murphy Journal: Circ Res Date: 2010-04-22 Impact factor: 17.367
Authors: Dao-Fu Dai; Luis F Santana; Marc Vermulst; Daniela M Tomazela; Mary J Emond; Michael J MacCoss; Katherine Gollahon; George M Martin; Lawrence A Loeb; Warren C Ladiges; Peter S Rabinovitch Journal: Circulation Date: 2009-05-18 Impact factor: 29.690
Authors: Carlos Marques Palmeira; João Soeiro Teodoro; João Alves Amorim; Clemens Steegborn; David A Sinclair; Anabela Pinto Rolo Journal: Free Radic Biol Med Date: 2019-07-24 Impact factor: 7.376